| 6MWD | Six-minute walking distance |
| BPA | Balloon pulmonary angioplasty |
| BMPR2 | Bone morphogenetic protein receptor type 2 |
| BNP | Brain natriuretic peptide |
| CCBs | Calcium channel blockers |
| CPET | Cardiopulmonary Exercise Testing |
| ppm | Cases per million |
| CLD | Chronic lung disease |
| COPD | Chronic obstructive pulmonary disease |
| CTEPH | Chronic thromboembolic pulmonary hypertension |
| CPFE | Combined pulmonary fibrosis and emphysema |
| CHD | Congenital heart disease |
| CPAP | Continuous positive airway pressure |
| DECT | Dual-energy computed tomography |
| ERAs | Endothelin receptor antagonists |
| ESC | European Society of Cardiology |
| HF | Heart failure |
| HFmrEF | Heart failure with mildly reduced ejection fraction |
| HFpEF | Heart failure with preserved ejection fraction |
| HFrEF | Heart failure with reduced ejection fraction |
| HPAH | Heritable PAH |
| IPAH | Idiopathic PAH |
| IPF | Idiopathic pulmonary fibrosis |
| IL-6 | Interleukin-6 |
| ILD | Interstitial lung disease |
| LHD | Left heart disease |
| mPAP | Mean pulmonary arterial pressure |
| NO | Nitric oxide |
| PDE5i | Phosphodiesterase type 5 inhibitor |
| PDGF | Platelet-derived growth factor |
| PAs | Prostacyclin analogs |
| PRAs | Prostacyclin receptor agonists |
| PAH | Pulmonary arterial hypertension |
| PAWP | Pulmonary artery wedge pressure |
| PEA | Pulmonary endarterectomy |
| PH | Pulmonary hypertension |
| PPHN | Pulmonary hypertension of the newborn |
| PVR | Pulmonary vascular resistance |
| PVOD | Pulmonary veno-occlusive disease |
| RHC | Right heart catheterization |
| sGCS | Soluble guanylate cyclase stimulator |
| TGF-β | Transforming growth factor-beta |
| V/Q | Ventilation/perfusion |
| WU | Wood Units |
| WHO | World Health Organization |
| WSPH | World Symposium on Pulmonary Hypertension |